ArticleInternational journal of biological sciences2019
A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Article in International journal of biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis.The Journal of cell biology · 2024Article
- Characterization of starvation response-related genes for predicting prognosis in breast cancer.Cancer science · 2023Article
- Identifying cancer cell-secreted proteins that activate cancer-associated fibroblasts as prognostic factors for patients with pancreatic cancer.Journal of cellular and molecular medicine · 2022Article
- A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort.Aging · 2021Article
- Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma.Pathology oncology research : POR · 2021Article
- A new 7-gene survival score assay for pancreatic cancer patient prognosis prediction.American journal of cancer research · 2021Article
- Development and Validation of a Novel Metabolic-Related Signature Predicting Overall Survival for Pancreatic Cancer.Frontiers in genetics · 2021Article
- A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma.American journal of cancer research · 2021Article
- A Starvation-Based 9-mRNA Signature Correlates With Prognosis in Patients With Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma.Journal of translational medicine · 2020Article
- Construction of a 6-gene prognostic signature to assess prognosis of patients with pancreatic cancer.Medicine · 2020Observational
- Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.Journal of Cancer · 2020Article
- Identification of a 5-Gene Metabolic Signature for Predicting Prognosis Based on an Integrated Analysis of Tumor Microenvironment in Lung Adenocarcinoma.Journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. PDAC prognostic and diagnostic biomarkers are still being explored. The aim of this study is to establish a robust molecular signature that can improve the ability to predict PDAC prognosis. 155 overlapping differentially expressed genes between tumor and non-tumor tissues from three Gene Expression Omnibus (GEO) datasets were explored. A least absolute shrinkage and selection operator method (LASSO) Cox regression model was employed for selecting prognostic genes. We developed a 6-mRNA signature that can distinguish high PDAC risk patients from low risk patients with significant differences in overall survival (OS). We further validated this signature prognostic value in three independent cohorts (GEO batch,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.